Voreloxin
Anticancer Activity Demonstrated in Both Hematologic and Solid Malignancies
We are currently evaluating voreloxin in clinical trials of acute myeloid leukemia (AML) and platinum-resistant ovarian cancer. We have 2 ongoing trials in AML: a Phase 1b/2 combination clinical trial of voreloxin with cytarabine in patients with relapsed and/or refractory acute myeloid leukemia, as well as a Phase 2 single agent trial for elderly patients with newly diagnosed and previously untreated AML, known as REVEAL-1 (Response Evaluation of Voreloxin in AML).
Voreloxin has demonstrated objective tumor responses in a variety of tumor types and has been generally well tolerated. Clinical responses with single agent voreloxin have been seen in these indications, as well as in non-small cell and small cell lung cancers. In addition, complete remissions have been observed in AML patients treated with voreloxin in combination with cytarabine.
Voreloxin is a replication-dependent DNA-damaging agent that induces G2 arrest and apoptosis (cell death). As a result, cancer cells, which are typically proliferative and resistant to pathways that eliminate damaged or aberrant cells, are no longer able to divide and the cells die. Based on our translational research and our understanding of Voreloxin's mechanism of action, voreloxin has the potential to combine with other anticancer agents for the treatment of both advanced and earlier stage disease. Click here for more information on voreloxin's mechanism of action.
Voreloxin Presentations
Phase 1b/2 Pharmacokinetic/Pharmacodynamic Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory AML Patients.A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.Clinical Evidence of Mechanism-Based Pharmacodynamic Activity in Voreloxin-Treated AML Patients.
